Drugs / rMenB+OMV NZ
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01026974 | Feb → Sep 2010 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB+OMV NZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01026974 ↗ |
| Known as | 4CMenB | “investigational serogroup B meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or combined with an outer membrane vesicle from Neisseria...” PMID 23958808 ↗ Oct 2013 |
| Modality | Vaccine | “investigational serogroup B meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or combined with an outer membrane vesicle from Neisseria...” PMID 23958808 ↗ Oct 2013 |